Actinium-225 Prostate-specific Membrane Antigen Theranostics: Will α Beat β?

Nattakorn Dhiantravan1, Michael S Hofman1, Aravind S Ravi Kumar1

  • 1Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.

European Urology
|January 13, 2021
PubMed
Summary

Optimizing prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) depends on well-designed prospective trials. Future research should prioritize these studies for improved patient outcomes.